pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Kloxxado
drug
save

Kloxxado

Marketedupdated 3mo ago
by Hikma Pharmaceuticals USA Inc
Approved
community read0 votes

🐶 often sniffed alongside

top 8
  • tagApproval644 co-mentions · 280 sources
  • drugBUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE454 co-mentions · 227 sources
  • drugBRIXADI454 co-mentions · 227 sources
  • drugBUTRANS454 co-mentions · 227 sources
  • drugbuprenorphine ER454 co-mentions · 227 sources
  • drugbuprenorphine454 co-mentions · 227 sources
  • drugBUPRENORPHINE HYDROCHLORIDE454 co-mentions · 227 sources
  • drugSUBLOCADE454 co-mentions · 227 sources

all catalysts(0)

nothing on the calendar yet

Trials studying Kloxxado

  • phase2A Phase 2 Safety, Tolerability, PK, and Efficacy Study of CS-1103 Following Fentanyl Challenge With Naloxone Blockadenot yet recruitingn=16
  • phase1Pharmacodynamic Evaluation of Intranasal Nalmefenecompletedn=84
  • phase4A Phase 4 Clinical Study to Investigate the Efficacy and Safety of Naloxone HCI IV in Patients With Strokecompletedn=446
  • phase4Clinical Outcomes From Nalmefenewithdrawn

News(3)

  • Narcan maker Emergent BioSolutions eliminates top R&D role in sweeping restructuring
    Two and a half years into his tenure as Emergent BioSolutions CEO, Joseph Papa is executing another round of restructuring to align the business with “current business realities.”
    fiercebiotech · 8d ago
  • Trump administration will bring special ed to HHS
    Infant mortality rate dips, OTC naloxone options rise, and other health news from Morning Rounds
    stat · 1mo ago
  • FDA Broadens Access to Over-the-Counter Naloxone Nasal Spray for Opioid Overdose
    The U.S. Food and Drug Administration (FDA) today approved another over-the-counter (OTC) intranasal naloxone product, Rextovy, a 4 milligram (mg) naloxone hydrochloride nasal spray for the emergen…
    fda_press · 1mo ago
brand
Kloxxado
generic
naloxone hydrochloride
indication
Acute Opioid Overdosage
phase
marketed
Data sources
ClinicalTrials.gov
last refreshed 8m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?